PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
Basel – The 13th BioCamp has begun at Novartis’ headquarters in Basel, with more than 60 top students from international universities participating. This year’s focus is on how digitalisation will transform the pharmaceutical industry.
The three-day International Biotechnology Leadership Camp (BioCamp) brings together 60 top university students from 18 countries. This year’s focus is on digitalisation, which according to Novartis “has the potential to fundamentally transform biomedical research and the pharmaceutical business”. At the BioCamp, which is being held at Novartis’ headquarters in Basel, students and experts alike will explore the opportunities that come with the digital age.
“Digitalisation can foster progress in research and development, make clinical trials more efficient and patient-friendly and allow us to better understand who benefits most from which therapies,” said Novartis CEO Joseph Jiminez.
Increasingly more pharmaceutical companies are collaborating with IT companies, including Novartis, which is currently cooperating with Microsoft Research and multiple sclerosis (MS) experts to develop a tool that quantifies a MS patient’s level of disability in a non-invasive, patient-friendly manner.
The device, which measures a patient’s movements using a video sensor with machine learning algorithms, will be the basis of a workshop at the BioCamp, where participants will be asked to develop strategies on how to include this new technology in a clinical setting. The groups will present their strategy proposals to a jury of experts on the final day of the programme.